Sino Biopharmaceutical (HK:1177) has released an update.Don't Miss out on Research Tools:Discover the latest stocks recommended by top Wall ...

SINO BIOPHARM (01177.HK) injected its capital to the equity interests of LaNova Medicines with its self-raised funds, and ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...

MRK in-licenses a bispecific antibody, based on the same mechanism as SMMT's lead drug, which outperformed its blockbuster ...

AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...

MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...

LaNova Medicines leveraged ProBio's PD-1 molecule to develop its PD-1/VEGF bispecific antibody, a key component of the LM-299 ...

Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...

As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug ...

Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...